Mu and Delta Opioids Boost Dopamine in the Brain's Reward Center While Kappa Opioids Reduce It
Mu and delta opioid agonists increased dopamine release in the nucleus accumbens (reward center) while kappa agonists decreased it, providing direct neurochemical evidence for their opposing motivational effects.
Quick Facts
What This Study Found
Mu and delta opioids increase, while kappa opioids decrease, dopamine release in the nucleus accumbens. This differential modulation explains their opposing motivational effects.
Key Numbers
How They Did This
In vivo microdialysis in anesthetized rats measured dopamine and metabolites in the nucleus accumbens after intracerebroventricular injection of selective opioid agonists. Specific antagonists confirmed receptor selectivity.
Why This Research Matters
This provided direct neurochemical evidence for why different opioid types produce opposite emotional effects. Mu/delta activation drives reward-seeking; kappa activation drives avoidance.
The Bigger Picture
This is a landmark study in addiction neuroscience. It provided the direct neurochemical evidence that different opioid receptor types have opposite effects on the brain's reward signal (dopamine). This framework explains why kappa antagonists are being developed as antidepressants and why different opioid drugs produce different emotional effects.
What This Study Doesn't Tell Us
Study done in anesthetized rats, which may alter dopamine dynamics. Intracerebroventricular injection is not region-specific. Only one dose of each agonist was detailed.
Questions This Raises
- ?Could kappa antagonists treat depression by restoring dopamine signaling?
- ?Does chronic opioid use shift the balance from mu/delta toward kappa dominance?
Trust & Context
- Key Stat:
- Mu/delta increase, kappa decreases dopamine Opposing opioid receptor effects on nucleus accumbens dopamine directly explain reward vs. dysphoria
- Evidence Grade:
- Moderate-strength animal study using direct brain microdialysis. Provides real-time neurochemical evidence in living tissue.
- Study Age:
- Published in 1990. This finding is now foundational in addiction and mood neuroscience and has guided development of receptor-selective drugs.
- Original Title:
- The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study.
- Published In:
- Journal of neurochemistry, 55(5), 1734-40 (1990)
- Authors:
- Spanagel, R, Herz, A(14), Shippenberg, T S(2)
- Database ID:
- RPEP-00170
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why does dopamine in the nucleus accumbens matter?
The nucleus accumbens is the brain's reward center. Dopamine release here signals pleasure and motivation. More dopamine = reward feeling. Less dopamine = dysphoria and lack of motivation.
How does this relate to opioid addiction?
Mu opioid drugs like morphine increase reward center dopamine, creating pleasure. Over time, the brain compensates by increasing kappa activity, which reduces dopamine and creates dysphoria — driving continued drug use to feel normal.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00170APA
Spanagel, R; Herz, A; Shippenberg, T S. (1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study.. Journal of neurochemistry, 55(5), 1734-40.
MLA
Spanagel, R, et al. "The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study.." Journal of neurochemistry, 1990.
RethinkPeptides
RethinkPeptides Research Database. "The effects of opioid peptides on dopamine release in the nu..." RPEP-00170. Retrieved from https://rethinkpeptides.com/research/spanagel-1990-the-effects-of-opioid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.